IGFBP-2 partly mediates the early metabolic improvements caused by bariatric surgery

Cell Rep Med. 2021 Apr 20;2(4):100248. doi: 10.1016/j.xcrm.2021.100248.

Abstract

Insulin-like growth factor-binding protein (IGFBP)-2 is a circulating biomarker of cardiometabolic health. Here, we report that circulating IGFBP-2 concentrations robustly increase after different bariatric procedures in humans, reaching higher levels after biliopancreatic diversion with duodenal switch (BPD-DS) than after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). This increase is closely associated with insulin sensitization. In mice and rats, BPD-DS and RYGB operations also increase circulating IGFBP-2 levels, which are not affected by SG or caloric restriction. In mice, Igfbp2 deficiency significantly impairs surgery-induced loss in adiposity and early improvement in insulin sensitivity but does not affect long-term enhancement in glucose homeostasis. This study demonstrates that the modulation of circulating IGFBP-2 may play a role in the early improvement of insulin sensitivity and loss of adiposity brought about by bariatric surgery.

Keywords: BPD-DS; RYGB; bariatric surgery; binding protein; humans; insulin-like growth factor; metabolism; mice; patients; sleeve gastrectomy; type 2 diabetes.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bariatric Surgery* / methods
  • Biliopancreatic Diversion / methods
  • Biochemical Phenomena / physiology*
  • Gastrectomy / methods
  • Gastric Bypass / methods
  • Humans
  • Insulin-Like Growth Factor Binding Protein 2 / metabolism*
  • Mice
  • Obesity / surgery
  • Obesity, Morbid / metabolism
  • Obesity, Morbid / surgery*

Substances

  • IGFBP2 protein, human
  • Insulin-Like Growth Factor Binding Protein 2